Ionis Pharmaceuticals Stock Soars 11.6% on Earnings Beat

Ionis Pharmaceuticals' stock surged 11.6% in pre-market trading on April 25, 2025, driven by strong quarterly earnings that exceeded analysts' expectations.

The company reported earnings per share (EPS) of $0.66 for the quarter, surpassing the consensus estimate of $1.12 by $0.46. This positive earnings report has bolstered investor confidence in the company's financial performance and growth prospects.

Eversept Partners LP has disclosed a significant position in Ionis Pharmaceuticals, holding $7.52 million in the company's shares. This investment underscores the growing interest and optimism among institutional investors regarding Ionis Pharmaceuticals' future potential.